Drugs / mureletecan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004076 | Jun 1999 → ? | cancer of unknown primary site | University of Glasgow | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mureletecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004076 ↗ |
| Known as | Mag-camptothecin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108470 ↗ |
| Known as | Mag-cpt | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108470 ↗ |
| Known as | PNU-166148 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108470 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL2108470 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL2108470 ↗ |